Rüttinger D - Search Results

1

Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer.

Li R, Rüttinger D, Li R, Si LS, Wang YL. Li R, et al. Among authors: ruttinger d. Langenbecks Arch Surg. 2003 Dec;388(6):406-12. doi: 10.1007/s00423-003-0416-0. Epub 2003 Sep 19. Langenbecks Arch Surg. 2003. PMID: 14504933

2

Current immunotherapeutic strategies in lung cancer.

Rüttinger D, Hatz RA, Jauch KW, Fox BA. Rüttinger D, et al. Surg Oncol Clin N Am. 2007 Oct;16(4):901-18, x. doi: 10.1016/j.soc.2007.07.004. Surg Oncol Clin N Am. 2007. PMID: 18022551 Review.

3

Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.

Rüttinger D, van den Engel NK, Winter H, Schlemmer M, Pohla H, Grützner S, Wagner B, Schendel DJ, Fox BA, Jauch KW, Hatz RA. Rüttinger D, et al. J Transl Med. 2007 Sep 14;5:43. doi: 10.1186/1479-5876-5-43. J Transl Med. 2007. PMID: 17868452 Free PMC article. Clinical Trial.

4

Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein.

Rüttinger D, Li R, Poehlein CH, Haley D, Walker EB, Hu HM, Fox BA. Rüttinger D, et al. J Immunother. 2008 Jan;31(1):43-51. doi: 10.1097/CJI.0b013e318158fd16. J Immunother. 2008. PMID: 18157011

5

Immunotherapy for melanoma: the good, the bad, and the future.

Poehlein CH, Rüttinger D, Ma J, Hu HM, Urba WJ, Fox BA. Poehlein CH, et al. Among authors: ruttinger d. Curr Oncol Rep. 2005 Sep;7(5):383-92. doi: 10.1007/s11912-005-0066-1. Curr Oncol Rep. 2005. PMID: 16091201 Review.

6

Regression of bone metastases following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine draining lymph node cells.

Rüttinger D, Li R, Urba WJ, Fox BA, Hu HM. Rüttinger D, et al. Clin Exp Metastasis. 2004;21(4):305-12. doi: 10.1023/b:clin.0000046139.59515.4e. Clin Exp Metastasis. 2004. PMID: 15554386

7

Targeting and amplification of immune killing of tumor cells by pro-Smac.

Li R, Rüttinger D, Urba W, Fox BA, Hu HM. Li R, et al. Among authors: ruttinger d. Int J Cancer. 2004 Mar;109(1):85-94. doi: 10.1002/ijc.11655. Int J Cancer. 2004. PMID: 14735472 Free article.

8

Evaluation of a preclinical model of bone metastasis for the study of adoptive immunotherapy.

Rüttinger D, Li R, Urba WJ, Fox BA, Hu HM. Rüttinger D, et al. Eur Surg Res. 2003 Jul-Aug;35(4):346-51. doi: 10.1159/000070605. Eur Surg Res. 2003. PMID: 12802095

9

Manipulating the host response to autologous tumour vaccines.

Ma J, Poehlein CH, Jensen SM, LaCelle MG, Moudgil TM, Rüttinger D, Haley D, Goldstein MJ, Smith JW 3rd, Curti B, Ross H, Walker E, Hu HM, Urba WJ, Fox BA. Ma J, et al. Among authors: ruttinger d. Dev Biol (Basel). 2004;116:93-107; discussion 133-43. Dev Biol (Basel). 2004. PMID: 15603186

10

[DGFIT: Immune and targeted therapy in urologic oncology – what can be expected?].

Hegele A, Heinzer H, Rüttinger D, Siebels M. Hegele A, et al. Among authors: ruttinger d. Aktuelle Urol. 2012 Jul;43(4):219-26. doi: 10.1055/s-0032-1322498. Aktuelle Urol. 2012. PMID: 23035262 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results